Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Y-mAbs Therapeutics, Inc. logo — Innovative pediatric immunotherapies for Real-life Possibili...

Y-mAbs Therapeutics, Inc.

Innovative pediatric immunotherapies for Real-life Possibilities

Founded 2015 United States New York, United States 59 employees Post Ipo Equity Total: $338.80M Biotechnology, Health Care +1

General Information

Company Name Y-mAbs Therapeutics, Inc.
Founded Year 2015
Location United States New York, United States +2
Founders / Decision Makers
Team member
Employees 59
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Post Ipo Equity
Social

BounceWatch is an independent company data service, not affiliated with Y-mAbs Therapeutics, Inc.. To contact Y-mAbs Therapeutics, Inc., visit ymabs.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About Y-mAbs Therapeutics, Inc.

Y-mAbs Therapeutics, Inc. is a commercial-stage clinical biopharmaceutical company founded in 2015, headquartered in the United States. The company is dedicated to developing and commercializing innovative pediatric immunotherapies for the treatment of cancer. With a broad and advanced product pipeline, including pivotal-stage product candidates against a range of targets, Y-mAbs is positioned as a significant player in the Biotechnology and Health Care industries. Y-mAbs' mission is to lead the world in producing safer and more effective antibody-based oncology products to meet the unmet medical needs of both pediatric and adult patients. Their vision of changing the course of cancer care and outcomes is underpinned by the pursuit of the right partnerships and collaborations. The company has recently raised a substantial $115.00M investment in post-IPO equity. This significant investment occurred on 17 February 2021, signaling confidence from the investor community in the potential of Y-mAbs' innovative approach to pediatric immunotherapies. This recent investment is a testament to the company's potential for growth and impact in the biopharmaceutical sector. Y-mAbs’ commitment to addressing unmet medical needs in the field of oncology, particularly in pediatric care, positions the company as an attractive investment opportunity for venture capitalists seeking to support groundbreaking advancements in cancer treatment. With a clear focus and promising pipeline, Y-mAbs presents an intriguing possibility for investors looking to make an impact in the healthcare industry.

Taxonomy: pediatric immunotherapies, oncology products, antibody-based therapeutics, clinical biopharmaceutical company, cancer treatment, medical needs, pivotal-stage product candidates, commercial-stage, innovative therapies, biopharmaceutical, medical research, collaborations, partnerships, cancer care, patient outcomes

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity - Y •••••• - 17 Feb 2021
Post-IPO Equity - Y •••••• - 29 Oct 2019
Private Equity Round - Y •••••• 3
Investor Investor
•••• •••• 		29 Nov 2017
Private Equity Round - Y •••••• 1
Investor
24 Oct 2017

Y-mAbs Therapeutics, Inc. Alternatives & Competitors

Y-mAbs Therapeutics, Inc. vs
Apexigen
Apexigen United States

Creating Transformative Immunotherapies for Patients with Cancer

Post Ipo Equity
11 employees
Biopharma, Biotechnology
Compare Y-mAbs Therapeutics, Inc. vs Apexigen
Y-mAbs Therapeutics, Inc. vs
Atossa Therapeutics
Atossa Therapeutics

Providing innovative treatments for pre-cancerous breast conditions and early-stage breast cancer.

Post Ipo Equity
51-200 employees
Biotechnology, Health Care
Compare Y-mAbs Therapeutics, Inc. vs Atossa Therapeutics
Y-mAbs Therapeutics, Inc. vs
OncXerna Therapeutics
OncXerna Therapeutics United States

Advancing a new paradigm of precision oncology with a RNA-based approach to match patients to novel,...

Series Unknown
8 employees
Biopharma, Biotechnology
Compare Y-mAbs Therapeutics, Inc. vs OncXerna Therapeutics

FAQ About Y-mAbs Therapeutics, Inc.

Innovative pediatric immunotherapies for Real-life Possibilities
Y-mAbs Therapeutics, Inc. was founded in 2015.
Y-mAbs Therapeutics, Inc. is headquartered in New York, United States.
Y-mAbs Therapeutics, Inc. operates in the following industries: Biotechnology, Health Care, Health and Wellness.
Y-mAbs Therapeutics, Inc. has approximately 59 employees.
Y-mAbs Therapeutics, Inc. has completed 4 funding rounds, raising a total of $338.80M. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to Y-mAbs Therapeutics, Inc. include Apexigen, Atossa Therapeutics, OncXerna Therapeutics , Aurora Oncology, ORIC Pharmaceuticals Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Y-mAbs Therapeutics, Inc. and Apexigen are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Y-mAbs Therapeutics, Inc., https://bouncewatch.com/company/y-mabs-therapeutics-inc, updated 29 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes